What delayed care and waiting times cost in lives

The pandemic created a natural experiment nobody wanted: months in which routine diagnosis and treatment stopped, followed by waiting lists at record length in England and elsewhere. The evidence on what that costs is arriving, and it is uneven. For cancer, modelling and now registry data show later-stage diagnosis and a measurable mortality effect for some sites; for cardiovascular disease, delayed presentation and missed treatment are visible in excess deaths at home in 2020 and 2021. For elective care the picture is murkier: long waits for joint replacement or cataract surgery cost function and quality of life more than life, and the studies that link waiting time to mortality mostly find small effects confounded by who waits. England publishes waiting-time data of unusual detail, which is why so much of the evidence is English; other countries measure it differently or not at all. The question is whether waiting lists are a mortality story or a morbidity one, and for which conditions.

Status

emerging

Direction

strengthening

Would change our view

A linked study attributing deaths to waiting time for a defined condition with proper adjustment; or evidence that the pandemic-era cancer stage shift has reversed.

Trackers

Gaps

Waiting-time data comparable across countries; any mortality linkage outside England and a few Nordic studies; primary-care access as distinct from hospital waits.